LEGAL PROCEEDINGS (Details) (USD $) In Millions, unless otherwise specified	1 Months Ended				37 Months Ended	1 Months Ended					6 Months Ended	1 Months Ended	6 Months Ended	1 Months Ended	6 Months Ended	1 Months Ended				6 Months Ended
	May 31, 2008 Written plea agreement Biovail Pharmaceuticals, Inc.	May 31, 2008 Non-prosecution agreement Biovail Pharmaceuticals, Inc.	Sep. 30, 2009 Corporate Integrity Agreement Biovail Pharmaceuticals, Inc.	Oct. 31, 2009 General civil actions	Oct. 31, 2009 General civil actions	Mar. 31, 2011 Legacy Valeant Litigation	Feb. 28, 2010 Glumetza Apotex Inc.	Jan. 31, 2009 Quetiapine AstraZeneca Pharmaceuticals LP	Dec. 31, 2008 Quetiapine AstraZeneca Pharmaceuticals LP	Feb. 28, 2010 Aplenzin Watson	Jun. 30, 2011 Aplenzin Watson	Jan. 31, 2010 Aplenzin Paddock	Jun. 30, 2011 Aplenzin Paddock	Aug. 31, 2010 Aplenzin Par	Jun. 30, 2011 Aplenzin Par	Feb. 28, 2009 Permax	Aug. 31, 2008 Permax	Jun. 30, 2010 Wellbutrin XL Biovail Corporation	Dec. 31, 2009 Biovail Corporation	Jun. 30, 2011 Tolmar
Legal proceedings and other matters
Penalty fees	$ 22.2	$ 2.4
Obligation term (in years)			5
Dosage strength (in mg)							500 mg		200 mg, 300 mg and 400 mg	174 mg and 348 mg		174 mg and 522 mg		174 mg and 348 mg				150 mg and 300 mg
Period of stay on approval (in months)								30		30										30
Number of actions consolidated into the first-filed case											2
Number of the patents that remain in the litigation											5
Number of patents listed in the FDA's Orange Book													6		8
Number of cases settled				3		5
Number of claims filed					3	6
Number of other companies named as defendants																			20
Number of complaints served																	6
Number of motions responded for partial summary judgment																2
Maximum number of days in which lawsuit was filed (in days)																				45